NASDAQ · DTIL
Precision BioSciences, Inc.
$7.25-$0.19 (-2.55%)
Precision BioSciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.64% below the high.
Loading market information…
OTC · OMMH · USD
Stock price
Quote as of Jul 17, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Omnimmune Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:33 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.25-$0.19 (-2.55%)
Precision BioSciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.64% below the high.
$3.15-$0.15 (-4.55%)
Anixa Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.31% below the high.
$2.05-$0.19 (-8.48%)
Minerva Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.7% below the high.
$1.71-$0.04 (-2.29%)
CervoMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.9% below the high.
$0.05+$0.01 (+33.06%)
Oncology Pharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.84% below the high.
$0.00$0.00 (0.0%)
Quick-Med Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.5% below the high.
$0.00$0.00 (0.0%)
GeneLink, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Arno Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
